Member Info for shatter

Maybe spoke too soon.

Going in the right direction for a change;-)

859p to sell so no negative impact as yet..

Oxford Biomedica announces update to agreement with Sio Gene Therapies
Oxford Biomedica announces that S io Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease

N egligible financial impact on Oxford Biomedica in the short and medium term
Non - core, legacy asset to be returned and out-licensed again in due course

Oxford, UK – 3 1 January , 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. This follows Sio’s announcement today about the resignation of their CEO where Sio also indicates a constraint on resource requirements that has caused Sio to deprioritise the programme. All rights shall be returned to Oxford Biomedica at no cost to the Company.

Rns…someone’s working late tonight. No loss of revenue so may not have much impact on the sp.

And up she goes.. some multiple reasonable sized buys going through.

Hi Kern,
The CEO leaving at this time definitely raises the question “why”. Homology is haemorrhaging money and it’s share price has only gone one way for years. Appreciate that OXB now have a manufacturing facility in America but at what cost?
973 trades as I write this and the sp is static for a normally very volatile share !
It’s probably just me but I have fallen out of love with this share now. I only have 25% of my holding left but if the rot continues that’s going too.
As you say hopefully reached bottom now but never envisaged that we would be sub £10 let alone this price.
Keep the faith :-(

Matthew Treagus, Chief Information Officer, has purchased 594 ordinary shares of 50p each ("Ordinary Shares") in the Company on 28 January 2022 on the London Stock Exchange at a price of 841.7p. Even he doesn’t know what is going on ;-)

Very quiet here today . I think most expected and hoped for a bounce but the sp seems to be held back as usual. In the scheme of things Homology was not a big purchase but unfortunately Oxb still had to have a placing and loan to purchase 80% of it. This has lost 50% of its value recently. If it wasn’t for the vaccine production I dread to think where we would be.
Let’s hope that Homologys’ fortunes can turn around and it can start paying for itself.

It’s a mystery. There are some big shareholders such as Vulpes who must be livid at the drop. Perhaps the perfect storm….the markets are in the doldrums and many pharma have faired badly and perhaps it the sp has been manipulated with the automated trades?
Perhaps a good bounce later today but where this is going over the next few months is anyone’s guess?

Net loss for the quarter ended September 30, 2021 was $(30.6) million or $(0.54) per share, compared to a net loss of $(28.2) million or $(0.62) per share for the same period in 2020.
Total operating expenses for the quarter ended September 30, 2021 were $32.3 million, compared to $28.8 million for the quarter ended September 30, 2020, and consisted of research and development expenses and general and administrative expenses.
Oxb must be very confident that they can bring something to the table and turn around the fortunes of this company as cashburn is a real issue and R&D is very expensive and slow. Sounds like the early days of Oxb….Homology say they have funds that will see them through to q1 2023.

At least it’s the weekend now. Not sure what is going to change sentiment here in the short term !

“A drug interaction is a change in the action or side effects of a drug caused by concomitant administration with a food, beverage, supplement, or another drug.”
Bless :-)

The CEO departing recently is a little strange. If this is such a great deal why not hang around until completed. The new companies share price has performed very poorly over the last 5 years, obviously needs a cash injection and could be quite costly to run.
Hopefully Oxb haven’t got to big for their boots..

Would make you wonder if the recent sp has been manipulated at the expense of the pi’s to allow certain investors to buy into this new issue at a cheap price? On the plus side this is perhaps only a temporary blip! All very complicated.

Slightly hungover this morning. Seems to be scant on detail and overly complicated. One thing for sure is Oxb would make a great boat….it never leaks!

I think the recent fall here has caught many of us on the hop. My portfolio is down but saved by banking stocks but my Baillie Gifford and Legal and Generals funds have taken a real hit. Was close to selling some Aviva ( biggest holding)on Monday and banking some profit but managed to sit on my hands luckily as it is heading back towards its year high.
Kern, your recent buy could seem like good value in a few months. Keep well.

They did mention a few months ago that the court case was likely to take 2 years. As others have said a contract, however small, would be appreciated now.

“Concomitant”…. Now that’s a word you don’t see everyday.

Is this the start of a recovery or just a couple of good days? Answers on a postcard.